INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Recro Pharma, Inc.
NEW YORK--(BUSINESS WIRE)--Jun 3, 2018--Levi & Korsinsky announces it has commenced an investigation of Recro Pharma, Inc. (“Recro” or “the Company”) (NASDAQCM: REPH) concerning possible violations of federal securities laws.
On May 24, 2018, Recro revealed that the U.S. Food & Drug Administration (the “FDA”) had declined to approve Recro’s New Drug Application for the non-opioid pain relief treatment IV meloxicam. The FDA stated in its Complete Response Letter that the drug’s analgesic effects did not meet its expectations and raised questions related to certain data included in the NDA. Following this news, Recro stock fell 54.7% to close at $5.63 per share on May 24, 2018. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180603005022/en/
CONTACT: Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: 877-363-5972
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL
SOURCE: Levi & Korsinsky, LLP
Copyright Business Wire 2018.
PUB: 06/03/2018 05:00 PM/DISC: 06/03/2018 05:01 PM